A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma

NCT07011056 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

390

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent and Refractory Diffuse Large B-cell Lymphoma

Interventions

DRUG: Purinostat Mesylate for Injection
DRUG: Selinexor Tablets

Sponsor

Chengdu Zenitar Biomedical Technology Co., Ltd